OBJECTIVE:To evaluate the human body pharmacokinetics and bioequiavailability of two kinds of oral single dose of hydrochloric itraconazole capsules.METHODS:A randomized,crossover study of20healthy volunteers receiving sin-gle oral dose of200mg itraconazole was conducted with in vivo blood concentrations determined by HPLC-fluorescence de-tection.RESULTS:The pharmacokinetic parameters for the testing itraconazole and the reference itraconazole were as fol-lows,t 1/2 were(29.3?5.62)h and(29.3?5.81)h,respectively;C max were(81.4?60.0)?g/L and(77.8?45.2)?g/L,respec-tively;t max were(3.9?0.70)h and(4.2?0.70)h,respectively;AUC 0～72 were(1199.4?649.6)(?g?h)/L and(1174.3?701.9)(?g?h)/L,respectively;AUC 0～∞ were(1414.0?815.2)(?g?h)/L and(1386.1?735.8)(?g?h)/L,respectively.there were no significant differences in main pharmacokinetics parameters between2preparations,except in t max from analysis of variance and one-side&two-sides t-tests.The relative bioavailability of trial itraconazole capsule was(105.3?23.4)%.CONCLUSION:These two kinds of itraconazole capsules are bioequivalent.

OBJECTIVE:To explore the role of clinical pharmacists providing pharmaceutical care for hemodialysis patients complicated with subacute infective endocarditis(IE). METHODS:Clinical pharmacists participated in the anti-infection treatment for a hemodialysis patients complicated with subacute IE,according to the antimicrobial spectrum,laboratory and imaging find-ings,and patient’s condition changes,assisted physician to optimize the regimen,clinical pharmacists suggested to give imipenem cilastatin sodium after hemodialysis,adjust the initial dose of teicoplanin and give 1 g vancomycin firstly,and maintained 0.5 g af-ter hemodialysis,then adjust its dose based on blood plasma concentration;during treatment,clinical pharmacists closely observed the treatment effect and adverse reactions,providing blood plasma concentration monitoring,medication reminding and medication education. RESULTS:Physicians adopted parts of suggestions of clinical pharmacists,no fever was found,hemogram returned to normal,no abnormal echocardiography,and patient discharged. CONCLUSIONS:Clinical pharmacists guarantee the safety and ef-ficacy of drug use by adopting dose of anti-infection drugs,evaluating efficacy,monitoring adverse reactions and vancomycin plas-ma concentration,and assisting physicians to optimize treatment regimen.

Objective : To establish a RP-HPLC method for the determination and pharmacokinetic study of loratadine in Chinese healthy volunteers. Methods; Chrornatography was performed on a Hypersil-BDS with acetonitrile-water (65 : 35, pH was adjusted to 3. 8 with H3PO4) as mobile phase. The flow rate was 1. 0 ml/min and the UV wavelength was set at 248 nm. Results: Good linearity was found within 0. 506 0-50. 60 ng/ml of loratadine in human plasma(r = 0. 999 5). The mean relative recovery rate was more than 95% ; intra-day and inter-day RSD were less than 15. 0%. The limit of detection was 0. 506 ng/ml. The main pharmacokinetic parameters were as follows:t12 was (1. 57 ? 0. 18) h;MRT was (2. 46?0. 19) h;Cl/ F was (583. 7?215. 0) L/h;cmax, was (37. 40?8. 92) ng/ml;tmax was (1. 0?0. 20) h;AUC0-8h was (73. 24?21. 30) ng ? h/ ml;.AUC/C0-∞ was (75. 57?21. 70) ng ? h/ml. Conclusion: Our method has a good selectivity and sensitivity and can be used for further clinical pharmacokinetic study of loratadine.